Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jameson Travers

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Environmental Health Perspectives|April 12, 2021
Profiling the Tox21 Chemical Collection for Acetylcholinesterase InhibitionShuaizhang Li, Jinghua Zhao, Ruili Huang, et al.
Environmental Health Perspectives|June 6, 2025
Expanded Tox21 biological assay panel for the prediction of drug-induced liver injury and cardiotoxicityTuan Xu, Masato Ooka, Jinghua Zhao, et al.
Environmental Health Perspectives|July 10, 2026
Expanded Tox21 Biological Assay Panel for the Prediction of Drug-Induced Liver Injury and CardiotoxicityTuan Xu, Masato Ooka, Jinghua Zhao, et al.
Toxicology and Applied Pharmacology|September 16, 2025
Systematic evaluation of Tox21 compounds that target β-adrenergic receptors and their role in cardiotoxicityXi Luo, Li Zhang, Srilatha Sakamuru, et al.
Cancer Research Communications|March 7, 2024
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine XenograftsYasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, et al.
Nature Communications|September 17, 2022
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaYandan Yang, Arnold Bolomsky, Thomas Oellerich, et al.
Molecular Cancer Therapeutics|October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Personality and Individual Differences|July 14, 2026
The effect of personality on likelihood of contracting SARS-CoV-2 in the United StatesJoshua K Wood, Sara J Weston, David M Condon, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United StatesTran B Ngo, Maria Karkanitsa, Kenneth M Adusei, et al.
Cancer Cell|April 13, 2021
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stressAnish Thomas, Nobuyuki Takahashi, Vinodh N Rajapakse, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Environmental Health Perspectives|April 12, 2021
Profiling the Tox21 Chemical Collection for Acetylcholinesterase InhibitionShuaizhang Li, Jinghua Zhao, Ruili Huang, et al.
Environmental Health Perspectives|June 6, 2025
Expanded Tox21 biological assay panel for the prediction of drug-induced liver injury and cardiotoxicityTuan Xu, Masato Ooka, Jinghua Zhao, et al.
Environmental Health Perspectives|July 10, 2026
Expanded Tox21 Biological Assay Panel for the Prediction of Drug-Induced Liver Injury and CardiotoxicityTuan Xu, Masato Ooka, Jinghua Zhao, et al.
Toxicology and Applied Pharmacology|September 16, 2025
Systematic evaluation of Tox21 compounds that target β-adrenergic receptors and their role in cardiotoxicityXi Luo, Li Zhang, Srilatha Sakamuru, et al.
Cancer Research Communications|March 7, 2024
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine XenograftsYasuhiro Arakawa, Ukhyun Jo, Suresh Kumar, et al.
Nature Communications|September 17, 2022
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaYandan Yang, Arnold Bolomsky, Thomas Oellerich, et al.
Molecular Cancer Therapeutics|October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Personality and Individual Differences|July 14, 2026
The effect of personality on likelihood of contracting SARS-CoV-2 in the United StatesJoshua K Wood, Sara J Weston, David M Condon, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United StatesTran B Ngo, Maria Karkanitsa, Kenneth M Adusei, et al.
Cancer Cell|April 13, 2021
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stressAnish Thomas, Nobuyuki Takahashi, Vinodh N Rajapakse, et al.
Pageof 3